The mission of the Genomics Shared Resource (GSR) is to provide state-of-the-art genomic services to Cancer Therapy and Research Center (CTRC) members in an economical and timely manner. The GSR has been in operation since the inception of the Cancer Center Support Grant (CCSG) in the early 1990's. Originally, the shared resource focused on cytogenetic services under the leadership of Dr. John McGill. Dr. McGill left the University in 2000, and Dr. Robin Leach became Director of the Cytogenetics Shared Resource. Although the Shared Resource began expanding to non-cytogenetic services in 2001, it was only renamed the Genomics Shared Resource in the 2008 competitive renewal of the CCSG. The GSR is located within 1,470 sq.ft. on the UTHSCSA Long Campus. The GSR provides state-of-the-art services as well as intellectual expertise with a range of molecular genetic assays that complement the interests, needs and existing resources of its users. The GSR provides access to both high throughput and custom genotyping of single nucleotide polymorphisms using the lllumina iScan and BeadXpressGoldenGate technologies and TaqMan allelic discrimination analysis on the Life Technologies 7900HT Sequence Detection System. It also offers whole genome gene expression microarray analysis using the lllumina iScan. In addition, the GSR offers services for quantity and quality assessment of nucleic acids (Nanodrop spectrophotometer) and Agilent Bioanalyzer. Finally, the GSR provides support for sample processing by providing services for isolating nucleic acids, as well as transforming lymphocytes to establish lymphoblastoid cell lines using Epstein-Barr virus. The GSR staff consists of the Director, Robin J. Leach, Ph.D., Co-Director, Teresa L. Johnson-Pais, Ph.D. and Research Associate, Mandy R. Hinojosa. GSR services supported 10- peer-reviewed funded cancer center members, which accounted for 29% of the total users and 47% of the samples evaluated by the core during the last award year.

Public Health Relevance

In this era of personalized medicine, genetic variation has been shown to be important in both the development and progression of cancer and genetic variants have also been utilized to predict response to clinical therapies. In addition, gene expression studies have proven useful for stratifying cancers and understanding the role of specific genes. The GSR provides the expertise and newest technologies for both genotyping and gene expression studies to cancer center members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758374
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$82,893
Indirect Cost
$39,733
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014
Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185
Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10
Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190

Showing the most recent 10 out of 853 publications